A little-known biotech's high-stakes cancer bet just paid off and its shares doubled

Impact · against what's priced in

Genmab is the primary beneficiary, having fundamentally pivoted its business model from royalty-collection to full ownership of multi-billion dollar assets, though the market has already aggressively priced in the recent Phase 3 wins. For Merck and J&J, the news is marginally positive but largely confirmatory of existing franchise strength and does not shift the needle on their core valuation drivers.

MRK+0.10

Challenges what's priced in

The price assumes